Position in SLNO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,004,400
+$443,518 QoQ
Shares Held
30,000
+282.2% QoQ
Ownership
0.058%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#114
of 224 holders
Holding Since
Dec 2024
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SLNO Over Time
Shares Held
Position Value (USD)
Derivatives in SLNO
reported options exposure · as of Mar 31, 2025CallValue
$1,071,750
CallShares
15,000
PutValue
$1,614,770
PutShares
22,600
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026CANTOR FITZGERALD, L. P. holds $25,602,427 across 21 Biotechnology names. SLNO ranks #7 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IMCR |
Immunocore Holdings plc
|
250,211 | $7,543,861 | |
| 2 | RNA |
Atrium Therapeutics, Inc.
|
235,637 | $3,150,466 | |
| 3 | CABA |
Cabaletta Bio, Inc.
|
765,000 | $2,057,850 | |
| 4 | VSTM |
Verastem, Inc.
|
363,132 | $1,924,599 | |
| 5 | INSM |
INSMED Inc
|
11,000 | $1,798,720 | |
| 6 | ACOG |
Alpha Cognition Inc.
|
188,631 | $1,035,584 | |
| 7 | SLNO |
Soleno Therapeutics Inc
This page
|
30,000 | $1,004,400 | |
| 8 | RCUS |
Arcus Biosciences, Inc.
|
45,000 | $972,000 |
All Filings in SLNO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,004,400 | 30,000 | Shares | Defined | 2026-05-15 | |
| 2025-03-31 | $1,071,750 | 15,000 | Call | Defined | 2025-05-15 | |
| 2025-03-31 | $560,882 | 7,850 | Shares | Defined | 2025-05-15 | |
| 2025-03-31 | $1,614,770 | 22,600 | Put | Defined | 2025-05-15 | |
| 2024-12-31 | $218,007 | 4,850 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||